TTP/HUS and prognosis: The syndrome and the disease(s)

Kidney International

Volumn 75, Issue SUPPL. 112, 2009, Pages

  Forzley, Brian R ^a   Clark, William F ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Clinical characteristics; Mortality; Plasma exchange; Prognosis; TTP HUS

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CLINICAL FEATURE; CONFERENCE PAPER; DISEASE REGISTRY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; CLASSIFICATION; EPIDEMIOLOGY; NOMENCLATURE; RECURRENT DISEASE; REGISTER; REVIEW; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); HEMOLYTIC-UREMIC SYNDROME; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REGISTRIES; RISK FACTORS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 61949150402     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.623     Document Type: Conference Paper

References (19)

1. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-67.
2. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279.
3. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035-1050.
4. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003; 1: 632-634.
5. Hovinga JA, Studt JD, Alberio L et al. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004; 41: 75-82.
6. Matsumoto M, Yagi H, Ishizashi H et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
7. Bell WR, Braine HG, Ness PM et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
8. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
9. Vesely SK, George JN, Lammle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
10. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563.
11. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400.
12. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995; 122: 569-572.
13. Dervenoulas J, Tsirigotis P, Bollas G et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 2000; 79: 66-72.
14. Shamseddine A, Saliba T, Aoun E et al. Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. J Clin Apheresis 2004; 19: 119-124.
15. Gurkan E, Baslamisli F, Guvenc B et al. Thrombotic thrombocytopenic purpura in southern Turkey: a single-center experience of 29 cases. Clin Lab Haematol 2005; 27: 121-125.
16. Forzley BR, Sontrop JM, Macnab JJ et al. Treating TTP/HUS with plasma exchange: a single centre's 25-year experience. Br J Haematol 2008; 143: 100-106.
17. Tuncer HH, Oster RA, Huang ST et al. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion 2007; 47: 107-114.
18. Wyllie BF, Garg AX, Macnab J et al. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 2006; 132: 204-209.
19. Pereira A, Mazzara R, Monteagudo J et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995; 70: 319-323.